EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Delta

Ensembl ID : ENSSFOG00015026232
Gene Symbol: GABRD
3 Cross references
193 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma1

Ensembl ID : ENSSFOG00015031641
Gene Symbol: GABRG1
1 Cross references
188 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSSFOG00015000943
Gene Symbol: GABRG2
3 Cross references
136 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma2

Ensembl ID : ENSSFOG00015002914
Gene Symbol: GABRG2
3 Cross references
206 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSFOG00015006679
Gene Symbol: GABRG3
1 Cross references
276 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSSFOG00015008960
Gene Symbol: GABRG3
3 Cross references
276 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSSFOG00015015917
Gene Symbol: GABBR1
3 Cross references
189 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSSFOG00015019934
Gene Symbol: GABBR1
3 Cross references
189 Possible Orthologues:

Gamma-Secretase Subunit Aph-1b

Ensembl ID : ENSSFOG00015021708
Gene Symbol: LOC108940818
3 Cross references
184 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSSFOG00015004388
Gene Symbol: GCGR
1 Cross references
185 Possible Orthologues:

Glucocorticoid Receptor-Like

Ensembl ID : ENSSFOG00015018348
Gene Symbol: LOC108936826
3 Cross references
206 Possible Orthologues:

Glucokinase

Ensembl ID : ENSSFOG00015019756
Gene Symbol: GCK
3 Cross references
209 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).